Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of$0.97. This compares to loss of $2.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.25$1.28 per share when it actually produced a loss of $0.80, delivering a surprise of 37.50%. Over the last four quarters, the c ...